Various surgical procedures may cause temporary interruption of spinal cord
blood supply and may result in irreversible ischemic injury and neurologic
al deficits. The cascade of events that leads to neuronal death following i
schemia may be amenable to pharmacological manipulations that aim to increa
se the tolerable duration of ischemia. Many agents have been evaluated in e
xperimental spinal cord ischemia (SCI). In order to investigate whether an
agent is available that justifies clinical evaluation, the literature on ph
armacological neuroprotection in experimental SCI was systematically review
ed to assess the neuroprotective efficacy of the various agents. In additio
n, the strength of the evidence for neuroprotection was investigated by ana
lyzing the methodology. The authors used a systematic review to conduct thi
s evaluation. The included studies were analyzed for neuroprotection and me
thodology. In order to be able to compare the various agents for neuroprote
ctive efficacy, relative risks and confidence intervals were calculated fro
m the data in the results sections. A total of 103 studies were included. S
eventy-nine different agents were tested. Only 14 of the agents tested did
not afford protection at all. A large variation was observed in the experim
ental models to produce SCI. This variation limited comparison of the indiv
idual agents. In 48 studies involving 31 single agents, the relative risks
and confidence intervals could be calculated. An analysis of the methodolog
y revealed poor temperature management and lack of statistical power in the
majority of the 103 studies. The results suggest that numerous agents may
protect the spinal cord from transient ischemia. However, poor temperature
management and lack of statistical power severely weakened the evidence. Co
nsequently, clinical evaluation of pharmacological neuroprotection in surgi
cal procedures that carry a risk of ischemic spinal cord damage is not just
ified on the basis of this study.